News Related to Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Related coverage linked through entity extraction aliases.

FDA Approves Monthly Dosing for Rybrevant Faspro in EGFR-Mutated NSCLC, Grants Breakthrough Status

Feb 17, 2026

The FDA has approved a monthly dosing schedule for Rybrevant Faspro in EGFR-mutated NSCLC and granted breakthrough therapy designation for the drug as monotherapy in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.

FDA Approves Monthly Dosing Schedule for Rybrevant Faspro in EGFR-Mutated Lung Cancer

Dec 18, 2025

The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.